drugset
drugset / Trial / NCT02243007

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

NCT02243007 ↗

Phase 2 Terminated 7 enrolled Massachusetts General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.

Timeline

Start
2014-09
Primary completion
2016-06
Completion
2016-06

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous
Subject Nab-paclitaxel Small molecule — Intravenous
Background Capecitabine Small molecule — —

Indications

pancreatic ductal adenocarcinoma